Technical Analysis for DECA - Denali Capital Acquisition Corp.

Grade Last Price % Change Price Change
B 11.65 0.00% 0.00
DECA closed unchanged on Thursday, November 14, 2024, on 0 percent of normal volume.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Very Strong Up Up Flat

Date Alert Name Type % Chg
Calm After Storm Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
Inside Day Range Contraction 0.00%
20 DMA Support Bullish 0.00%
Calm After Storm Range Contraction 0.00%
Gapped Down Weakness 0.00%
20 DMA Support Bullish 0.09%
50 DMA Support Bullish 0.09%
Jack-in-the-Box Bullish Bullish Swing Setup 0.09%
Inside Day Range Contraction 0.09%

   Recent Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Denali Capital Acquisition Corp., a blank check company, intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or related business combination with one or more businesses or entities.
Classification

Keywords: Private Equity Mergers And Acquisitions Special Purpose Acquisition Company Reverse Takeover

Is DECA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Recent News

Date Title
Oct 28 Scilex Holding Company sets November 7, 2024 as the Record Date for a Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary
Oct 11 Denali Capital Acquisition Corp. announces extension of deadline to complete business combination
Sep 3 Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Announce Signing of a Merger Agreement for a proposed Business Combination, Providing for a Pre-Transaction Equity Va...
Sep 3 Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Announce Signing of a Merger Agreement for a proposed Business Combination
Jul 10 Denali Capital Acquisition Corp. Announces Shareholder Approval of Extension of Deadline to Complete Business Combination
Jul 2 Semnur Pharmaceuticals and Denali Capital Acquisition enter into a letter of intent for proposed business combination
Jul 2 Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Enter into a Letter of Intent for a Proposed Business Combination
Jun 27 Correction: Denali Capital Acquisition Corp. and Longevity Biomedical, Inc. Mutually Agreed to Terminate the Business Combination
Jun 27 Top Midday Gainers
Jun 27 Denali Capital Acquisition Corp. and Longevity Biomedical, Inc. Mutually Agreed to Terminate the Business Combination
See more DECA news...

Indicators

Indicator Value
52 Week High 14.1
52 Week Low 4.05
Average Volume 3,471
200-Day Moving Average 8.65
50-Day Moving Average 11.52
20-Day Moving Average 11.59
10-Day Moving Average 11.62
Average True Range 0.18
RSI (14) 53.70
ADX 51.85
+DI 40.57
-DI 9.61
Chandelier Exit (Long, 3 ATRs) 11.46
Chandelier Exit (Short, 3 ATRs) 11.88
Upper Bollinger Bands 11.87
Lower Bollinger Band 11.32
Percent B (%b) 0.6
BandWidth 4.78
MACD Line 0.08
MACD Signal Line 0.09
MACD Histogram -0.0101
Fundamentals Value
Market Cap 52.87 Million
Num Shares 4.54 Million
EPS -2.49
Price-to-Earnings (P/E) Ratio -4.68
Price-to-Sales 0.00
Price-to-Book 0.40
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 11.65
Resistance 3 (R3) 11.65 11.65 11.65
Resistance 2 (R2) 11.65 11.65 11.65 11.65
Resistance 1 (R1) 11.65 11.65 11.65 11.65 11.65
Pivot Point 11.65 11.65 11.65 11.65 11.65
Support 1 (S1) 11.65 11.65 11.65 11.65 11.65
Support 2 (S2) 11.65 11.65 11.65 11.65
Support 3 (S3) 11.65 11.65 11.65
Support 4 (S4) 11.65